Pangenia

What Pangenia does

Pangenia Inc is a Hong Kong-headquartered molecular diagnostics group operating six wholly-owned subsidiaries: DiagCor Bioscience (prenatal DNA testing, NIPT, paternity), Pangenia Lifesciences (NGS-based testing, PGS/PGD), 22Plus (lifestyle genetics), Bio-Technology Limited (cervical screening, HPV), PanRARE Genomics (rare-disease center of excellence), and DiagCor Life Science (IVD products and global distribution). Founded in 2006 by Professor Joseph Wing-On Tam, the group runs ISO-certified laboratories in Hong Kong and Guangzhou (the latter operated via a 2016 wholly foreign-owned structure and a 2018 partnership with Shanghai Tongshu Biotech), and has accumulated over 700,000 clinical samples analyzed since inception.

The group's core technology stack combines patented flow-through hybridization (including the FTPro device), next-generation sequencing, qPCR, digital PCR, and Sanger sequencing, with patents registered in Hong Kong, Mainland China, Europe, and the United States. Pangenia monetizes through two parallel engines: (1) one-time laboratory service fees for genetic and diagnostic testing billed through its own facilities to hospitals, medical institutions, government health authorities, and individual patients; and (2) one-time IVD product sales — HPV kits, STD array kits, FTPro devices — distributed globally through channel partners including Asuragen, Embitec, Epigenomics, Taigen, and Promega across Latin America, Europe, the Middle East, and Southeast Asia.

Pangenia was acquired by Hong Kong-listed Mason Group Holdings Limited (00273.HK) in 2016 and operates as a privately held subsidiary under that group. Sales-led go-to-market motion is delivered through direct laboratory services, healthcare professional relationships, academic and medical conferences, and CSR-driven public engagement. Pricing is not publicly disclosed. In late 2020, Pangenia Lifesciences jointly launched an FDA-certified Three-in-One Detection Tool for COVID-19 and Influenza A/B with Hai Kang Life, the first such product launched in Hong Kong.

Name

Pangenia

Legal name

Pangenia Inc

Website

https://pangenia.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

251–500 employees

Short description

Pangenia Inc is a Hong Kong-headquartered molecular diagnostics group operating six subsidiaries that provide prenatal, cancer, infectious disease, and hereditary genetic testing services and distribute IVD products globally through channel partners.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Services

NAICS

Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Molecular diagnostics services
• Genetic testing services
• Prenatal screening tests
• In-vitro diagnostics products
• Hereditary risk assessment

Headquarters

HQ city

Kowloon City

HQ country

Hong Kong SAR China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Diagnostic Services: Molecular diagnostics laboratory services including genetic testing, prenatal diagnosis, parentage investigation, cancer testing, infectious disease identification, and hereditary risk assessments performed in company-owned laboratories.
2. In Vitro Diagnostic (IVD) Products: Manufacturing and commercialization of diagnostic products including HPV kits, flow-through hybridization devices and related test kits for global distribution.
3. Genetic Testing Services: Specialized genetic testing services including Non-Invasive Prenatal Testing (NIPT), PGS/PGD services, precision cancer tests, and hereditary risk assessments offered through Pangenia Lifesciences subsidiary.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Pangenia Group is a Hong Kong-based molecular diagnostics (MDx) group that operates ISO-certified clinical laboratories and develops, manufactures, and commercializes proprietary genetic testing services and in-vitro diagnostic (IVD) products. Its core offerings include prenatal testing (NIPT, PGS/PGD), cancer diagnostics, infectious disease detection (HPV, COVID-19/Influenza), paternity testing, and hereditary risk assessments, supported by patented flow-through hybridization technology, NGS, qPCR, digital PCR, and Sanger sequencing. The group serves both healthcare providers and individual patients across Hong Kong, China, and international markets through six wholly-owned subsidiaries.

Product overview

Pangenia Inc is a leading molecular diagnostics (MDx) group in Hong Kong operating as a platform of six subsidiaries providing genetic testing services. The core offerings include DiagCor Bioscience (prenatal testing, NIPT, paternity testing), Pangenia Lifesciences (NGS-based genetic testing, PGS/PGD services), 22Plus (personal lifestyle genetic tests), Bio-Technology Limited (cervical screening, HPV diagnostics), Pangenia Genomics/PanRARE (rare disease center of excellence), and DiagCor Life Science (flow-through hybridization technology for IVD products globally). The company leverages patented flow-through hybridization technology, next-generation sequencing (NGS), qPCR, digital PCR, and Sanger sequencing to provide diagnostic services across prenatal diagnosis, cancer testing, infectious disease identification, and hereditary risk assessments.

Differentiator

Problem solved

Functional benefit

Brands

• PanRARE CoE: First Asian center of excellence focused on Rare Diseases, providing quality diagnostic services for patients, doctors and scientists, building genomic database and patient registry through diagnosed patients in Asia

Products and services

• DiagCor Bioscience Laboratory Services First private MDx laboratory in Hong Kong providing one-stop prenatal DNA testing services including Non-invasive Prenatal Test (NIPT), Fragile X Carrier Screening, and Paternity Testing. Has analyzed over 500,000 MDx samples and obtained ISO 9001 certification for paternity testing service. Targets expectant parents, reproductive health clinics, and individuals requiring paternity verification.
• Pangenia Lifesciences Genetic Testing Services Genetic testing and advisory services using next-generation sequencing (NGS) and other methods including qPCR, digital PCR, patented flow-through hybridization, and Sanger sequencing. Services cover reproductive medicine, women's health, hereditary risk assessments, and precision cancer tests. First independent private laboratory licensed for PGS/PGD services in Hong Kong. Targets healthcare providers and patients requiring advanced genetic diagnostics.
• 22Plus Personal Lifestyle Genetic Tests Professional genetic testing services for personal lifestyle optimization including Potential Talent Discovery Test, Athletic Aptitude DNA Testing, Responsiveness to Dietary Nutrients Test, and Physical and Mental Health Test. Targets health-conscious consumers interested in lifestyle genetic insights.
• PanRARE Center of Excellence for Rare Diseases First Asian center of excellence focused on rare diseases, providing quality diagnostic services for patients, doctors, and scientists. Builds genomic database and patient registry, collaborates with Asian and US academia on therapeutic treatments (FSHD/SMA/Satellite Cells for muscle regeneration), and supports local and regional patient advocacy groups. Targets rare disease patients and their physicians.
• DiagCor Life Science IVD Products Global leader in flow-through hybridization technology, translating cutting-edge MDx research into proven practical market applications. Operations span primary research, clinical and market studies, manufacturing, commercialization, and global distribution. Serves clinical diagnostic markets in Latin America, Europe, Middle East, and South East Asia. Targets IVD distributors and clinical laboratories internationally.
• Bio-Technology Cervical Screening Services Specialist cervical screening service provider offering gynecological cytology testing including Conventional Pap Smear, Liquid-based cytology (ThinPrep Pap Test), and Human Papilloma Virus (HPV) molecular diagnostics. Targets women requiring cervical cancer screening and HPV detection.
• Three-in-One COVID-19/Influenza A/B Detection Tool Jointly developed detection tool with Hai Kang Life Science capable of simultaneously detecting COVID-19, Influenza A, and Influenza B. First of its kind in Hong Kong with FDA certification. Targets healthcare providers, public health authorities, and patients requiring rapid respiratory pathogen detection.

Quantifiable outcome

• Over 700,000 clinical samples analyzed in company laboratories since 2006
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

15 partnerships are on record, tiered major, core and minor.

• Hai Kang Life CorporationmajorStrategic or Co-development Partner · 19 December 2020Joint development of 'Three-in-One' testing tool launched December 2020, combining COVID-19, influenza A/B detection - a Hong Kong first. FDA certified technology for faster and more accurate results.
• Shanghai Tongshu Biotech Company LimitedmajorStrategic or Co-development Partner · 1 January 2018Strategic partnership with Shanghai Tongshu Biotech Company Limited for Guangzhou DiagCor Tongshu Medical Laboratory Company Limited, combining local market expertise with international quality standards.
• World Health Organization (WHO)majorStrategic or Co-development PartnerPangenia Group supports WHO millennium development goals with the aim of eradicating tuberculosis and other infectious diseases. Collaboration on global health initiatives.
• Children's Thalassemia FoundationcoreStrategic or Co-development PartnerActive participation in fundraising activities for the Children's Thalassemia Foundation, the first charity supporting research into genetic disorders affecting children and providing support services to families.
• Hong Kong Society of Molecular Diagnostic SciencescoreStrategic or Co-development PartnerResearch partnership for independent evaluation of tuberculosis diagnostic kit development and validation.
• The First Affiliated Hospital, Sun Yat-sen UniversitymajorStrategic or Co-development PartnerResearch collaboration on HER2 (Human epidermal growth factor receptor 2) amplification in breast cancer diagnostic development.
• University of Hong KongcoreStrategic or Co-development PartnerResearch partnership for HPV screening in Asian populations, leveraging HKU's academic research capabilities.
• Hong Kong University of Science and TechnologycoreStrategic or Co-development PartnerCollaboration on development of testing system for molecular diagnostics technology.
• City University of Hong KongcoreStrategic or Co-development PartnerResearch partnership using flow-through hybridization technology for mammalian species identification in food products.
• Chinese University of Hong KongcoreStrategic or Co-development PartnerPartnership for biomarkers development research collaboration.
• AsuragenminorChannel Partner/ Reseller/ DistributorCommercial partnership with US-based molecular diagnostics company for product distribution.
• EmbitecminorChannel Partner/ Reseller/ DistributorCommercial partnership with US-based biotech company for product distribution.
• EpigenomicsminorChannel Partner/ Reseller/ DistributorCommercial partnership with Germany-based company for molecular diagnostics product distribution.
• TaigenminorChannel Partner/ Reseller/ DistributorCommercial partnership with Taiwan-based company for product distribution in Asian markets.
• PromegaminorChannel Partner/ Reseller/ DistributorCommercial partnership with US-based life sciences company for reagent and product distribution.

Scale indicators5 records

Recent moves12 records

Expansion highlights6 records

Broad incumbents

• NeoGenomics: NeoGenomics is a US-based clinical laboratory and molecular diagnostics services provider focused on oncology, hematology, and rare disease testing. It is comparable as a multi-test-menu specialty clinical lab with molecular and NGS capabilities, though at a substantially larger US-centric scale.
• Roche Diagnostics: Roche Diagnostics is the world's largest in-vitro diagnostics company with broad molecular, immunoassay, and genomic test menus. It competes with Pangenia's IVD products and clinical lab offerings across multiple regions and serves as the benchmark global MDx incumbent.

Direct peers

• Kingmed Diagnostics: Kingmed Diagnostics is one of China's largest third-party medical diagnostic laboratory networks, providing pathology, molecular, and genetic testing services. It competes with Pangenia on clinical lab services for oncology, infectious disease, and hereditary testing in southern China.
• BGI Genomics: BGI Genomics is China's largest genomics and molecular diagnostics provider, offering NIPT, hereditary cancer testing, and infectious disease diagnostics. It directly competes with Pangenia across both clinical services and IVD products in Hong Kong and Mainland China, and represents the largest Asian MDx scale competitor.
• Novogene: Novogene is a leading China-based genomics services company providing NGS sequencing, bioinformatics, and genetic testing to researchers and clinicians. It overlaps with Pangenia Lifesciences on NGS-based hereditary risk and precision cancer testing services.
• Yourgene Health: Yourgene Health (part of the Novacyt group) is a UK-based molecular diagnostics company focused on NIPT, reproductive health, and infectious disease testing. It is a direct peer in NIPT/reproductive MDx and competes for IVD distribution partnerships across Asia.
• Berry Genomics: Berry Genomics is a leading Chinese NIPT and reproductive genetic testing company listed on ChiNext. It competes head-on with Pangenia Lifesciences in NIPT and hereditary testing, and has comparable NGS-based reproductive diagnostics capability.
• Da An Gene: Da An Gene is a major Chinese molecular diagnostics company specializing in PCR-based IVD kits for infectious disease, HPV, and genetic testing. It directly competes with DiagCor Life Science's IVD product lines and Pangenia's clinical infectious disease testing services in China.

Emerging players

• Natera: Natera is a US-based genetic testing company specializing in reproductive health (NIPT, PGS/PGT), oncology, and organ transplant monitoring. It represents the leading global pure-play in reproductive and hereditary genetic testing that Pangenia aspires to compete with internationally.

Regional players

• Guangzhou Kingmed Center (subsidiary under Kingmed): Kingmed's Guangzhou operations serve as a comparable regional clinical lab peer to Pangenia's Guangzhou DiagCor Tongshu Medical Laboratory, both serving the southern China market with advanced molecular diagnostics capabilities.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Pangenia-Group-640142839680275
• LinkedInlinkedin.com/company/pangenia-group

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pangenia